Endometrial growth inhibition by Urolithin A and B in an in vitro model of endometriosis

E ELGHONAIMY; RI BARAÑAO; D MADANES; M GÖTTE; B MCCORMACK; GF MERESMAN

Congreso; 35th Annual Meeting of the European Society of Human Reproduction and Embryology; 2019

ESHRE

tudy question: Do the ellagic acid metabolites Urolithin A (UroA) and B (UroB) affect human endometrial cell proliferation, cell cycle, and apoptosis in vitro?Summary answer: UroA and UroB treatment significantly alter proliferation, cell cycle and apoptosis of immortalized human endometrial stromal cells (ST-T1) and human epithelial-like endometriotic cells (12Z).What is known already: Endometriosis is a chronic disease with high recurrence rates. Nowadays, natural compounds are being considered for the treatment of diverse diseases. In particular, Ellagic acid (EA) has been widely demonstrated to have antioxidant and antitumoral properties. In previous work from our group, we demonstrated that EA induces cellular arrest of a stromal cell line in the G2/M phase of the cell cycle. UroA and UroB are metabolites of EA produced by the intestinal flora and are responsible for the anti-proliferative and pro-apoptotic properties of EA on tumor cells.Study design, size, duration: Both cell lines, ST-T1 and 12Z, were incubated with UroA or UroB for 24h, and subsequently evaluated for proliferation, cell cycle or apoptosis. All treatments were compared to the basal condition, and the tests were performed between 4 and 6 times each.Participants/materials, setting, methods: The urolithins? effects were assayed in ST-T1 and 12Z cell lines cultures. Briefly, cells were treated with 20 - 40 µM UroA and 5 - 10 - 20 µM UroB for 24 h. Cell proliferation was determined by a colorimetric assay using the MTT Cell Proliferation Kit, cell cycle distribution and percentage of apoptotic cells were determined using a flow cytometer.Main results and the role of chance: We observed that 40μM UroA significantly inhibited 12Z and ST-T1 cell proliferation (p